Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New multiple myeloma drug faces off against standard treatment in phase 1 trial

NCT ID NCT07477587

First seen Mar 19, 2026 · Last updated May 20, 2026 · Updated 6 times

Summary

This study tests whether a new drug called HLX15-SC works similarly to the approved drug DARZALEX FASPRO® for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 258 participants will receive either the new drug or the approved one, along with standard medications, for 4 cycles. The goal is to compare how the drugs move through the body, their safety, and how well they control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • American Oncology Network Vista Oncology Division / Physician partner associate

    Olympia, Washington, 98506, United States

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256, United States

  • D&H National Research Center

    Margate, Florida, 33063, United States

  • Florida Clinical Trials Group

    Plantation, Florida, 33322, United States

  • Florida Clinical Trials Group

    Tamarac, Florida, 33321, United States

  • Highlands Oncology Group, PA

    Springdale, Arkansas, 72762, United States

  • Oncology Consultants (P1 Trials -Exigent Network)

    Houston, Texas, 77030, United States

  • Pontchartrain Cancer Center

    Covington, Louisiana, 70433, United States

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200032, China

Conditions

Explore the condition pages connected to this study.